Based on the aggregated intelligence of 140,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company Human Genome Sciences (NASDAQ:HGSI) has received the dreaded one-star ranking.

With that in mind, let's take a closer look at Human Genome's business and see what CAPS investors are saying about the stock right now.

Human Genome facts

Headquarters (Founded)

Rockville, Md. (1992)

Market Cap

$3.1 billion

Industry

Biotechnology

Trailing-12-Month Revenue

$228.5 million

Management

CEO H. Thomas Watkins (since 2004)
CFO Timothy Barabe (since 2006)

Return on Capital (Average, Past 3 Years)

(14.8%)

6-Month Return

1,259%

Highly Rated Biotech Alternatives

Biogen Idec (NASDAQ:BIIB)
Amgen (NASDAQ:AMGN)
Genzyme (NASDAQ:GENZ)

CAPS Members Bearish on HGSI Also Bearish on

Targacept (NASDAQ:TRGT)
Dollar Thrifty Automotive (NYSE:DTG)

CAPS Members Bullish on HGSI Also Bullish on

Citigroup (NYSE:C)

Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.

On CAPS, 30% of the 552 members who have rated Human Genome believe the stock will underperform the S&P 500 going forward. These bears include bkwfool and UltraLong, the top-ranked stock picker in all of CAPS.

A few months ago, bkwfool seemed skeptical over the company's lupus drug results:

Hey, there has been lupus in my own family, so I know what a nasty disease it is. However, this "successful" trial was only marginally so, and [Human Genome] gets to share the benefits (which are years down the road even if future studies also show efficacy) with its partners. This jump to a $2B market cap is not sustainable. If I am wrong, it means a lot of lupus sufferers are buying some relief, so that makes this a winner to me either way.

In a pitch from the same day, UltraLong also tapped the stock's potential as being smaller than it seems:

They finally, after countless tries, found a drug that works better at controlling the pain and inflammation associated with lupus, potentially a 2 million person market. Now I'm not saying 2 million people aren't worth it, but perhaps they could have been lucky and pushed through a clinical trial for a drug that effects more than 0.0003% of the population.

So assuming this gets quick review status from the FDA, it will still be until early 2011 before any material impact is seen from the revenue of this drug. I would peg this as extremely unlikely to get this company to profitability. The underlying fundamentals here are a joke and always have been.

What do you think about Human Genome, or any other stock for that matter? Make your voice heard on Motley Fool CAPS today. The CAPS community is waiting to hear your opinions. CAPS is 100% free, so get started!  

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. The Fool's disclosure policy always gets a perfect score.